- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
MannKind (MNKD) is set to report 2016 second quarter results after Monday's market close.
MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.